Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pacira Pharm Inc
(NQ:
PCRX
)
14.26
+0.07 (+0.46%)
Streaming Delayed Price
Updated: 12:16 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
294,582
Open
14.29
Bid (Size)
14.24 (1)
Ask (Size)
14.25 (1)
Prev. Close
14.19
Today's Range
13.98 - 14.40
52wk Range
11.16 - 37.56
Shares Outstanding
44,454,792
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path
August 12, 2024
Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira's revenue, is now vulnerable,...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Where Pacira BioSciences Stands With Analysts
August 12, 2024
Via
Benzinga
Performance
YTD
-55.45%
-55.45%
1 Month
-28.83%
-28.83%
3 Month
-52.56%
-52.56%
6 Month
-52.07%
-52.07%
1 Year
-60.91%
-60.91%
More News
Read More
JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session
August 12, 2024
Via
Benzinga
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
August 09, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Expert Ratings For Pacira BioSciences
July 25, 2024
Via
Benzinga
NASDAQ:PCRX: good value for what you're paying.
June 26, 2024
Via
Chartmill
NASDAQ:PCRX, an undervalued stock with good fundamentals.
June 05, 2024
Via
Chartmill
Analyst Ratings For Pacira BioSciences
May 08, 2024
Via
Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
August 08, 2024
Via
Chartmill
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024
July 30, 2024
Via
InvestorPlace
Pacira BioSciences Reports Second Quarter 2024 Financial Results
July 30, 2024
From
Pacira BioSciences
Via
GlobeNewswire
3 Biotech Stocks to Buy on the Dip: July 2024
July 29, 2024
Via
InvestorPlace
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
July 23, 2024
From
Pacira BioSciences
Via
GlobeNewswire
In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
July 17, 2024
Via
Chartmill
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
July 10, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Top 5 Health Care Stocks That May Explode In July
July 08, 2024
Via
Benzinga
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
July 03, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
July 02, 2024
Via
Benzinga
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Pacira BioSciences
Via
GlobeNewswire
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
May 15, 2024
Via
Chartmill
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
May 10, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
May 08, 2024
From
Pacira BioSciences
Via
GlobeNewswire
PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
May 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.